Existing backer Gilead Sciences returned for a series B round that boosted the kidney disease therapy developer's total funding to $160m.

US-based kidney disease medication developer Goldfinch Bio, a closed an oversubscribed $100m series B round yesterday led by investment adviser Eventide Asset Management and backed by biopharmaceutical company Gilead Sciences. Wellington Management Company, Ally Bridge Group, Casdin Capital, Irving Investors, Yonjin Capital and Schroeder Adveq took part in the round, along with funds and accounts…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.